Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumab

Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumab Letters 4,5 Author Affiliations: Case Western Reserve University School of Medicine, action test. The relationship between the response to N+I Cleveland, Ohio (Dietz); University Hospitals Cleveland Medical Center, and biomarkers (eg, programmed cell death ligand 1 expres- Cleveland, Ohio (Pronovost). sion) or other characteristics of patients should not be re- Corresponding Author: Jill R. Dietz, MD, Case Western Reserve University jected until more in-depth studies in final end points were School of Medicine, 10900 Euclid Ave, Cleveland, OH 44106 (drjilldietz@ conducted. Therefore, it would be advisable to be cautious in gmail.com). clinical decision-making about the N+I scheme in neoadju- Published Online: December 10, 2020. doi:10.1001/jamaoncol.2020.6465 vant treatment of OCSCC until more mature data are avail- Conflict of Interest Disclosures: None reported. able on the benefit-risk ratio of treatment, efficacy in sub- 1. Dietz JR, Pronovost P. Time to focus on value-based metrics for cancer care? JAMA Oncol. 2020;6(9):1325-1326. doi:10.1001/jamaoncol.2020.0792 populations, and efficiency. 2. University of Utah. The state of value in US health care: University of Utah Value Survey 2018. Accessed November 4, 2020. https://uofuhealth.utah Manuel David Gil-Sierra, PharmD .edu/value/ Marina Sánchez-Hidalgo, PharmD 3. Woods L, Slotkin J, Coleman R. Transforming Health Care. Harvard Business Catalina Alarcón de la http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumab

Loading next page...
 
/lp/american-medical-association/clinical-decision-making-about-neoadjuvant-nivolumab-plus-ipilimumab-FPORZ5G5aW
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.6989
Publisher site
See Article on Publisher Site

Abstract

Letters 4,5 Author Affiliations: Case Western Reserve University School of Medicine, action test. The relationship between the response to N+I Cleveland, Ohio (Dietz); University Hospitals Cleveland Medical Center, and biomarkers (eg, programmed cell death ligand 1 expres- Cleveland, Ohio (Pronovost). sion) or other characteristics of patients should not be re- Corresponding Author: Jill R. Dietz, MD, Case Western Reserve University jected until more in-depth studies in final end points were School of Medicine, 10900 Euclid Ave, Cleveland, OH 44106 (drjilldietz@ conducted. Therefore, it would be advisable to be cautious in gmail.com). clinical decision-making about the N+I scheme in neoadju- Published Online: December 10, 2020. doi:10.1001/jamaoncol.2020.6465 vant treatment of OCSCC until more mature data are avail- Conflict of Interest Disclosures: None reported. able on the benefit-risk ratio of treatment, efficacy in sub- 1. Dietz JR, Pronovost P. Time to focus on value-based metrics for cancer care? JAMA Oncol. 2020;6(9):1325-1326. doi:10.1001/jamaoncol.2020.0792 populations, and efficiency. 2. University of Utah. The state of value in US health care: University of Utah Value Survey 2018. Accessed November 4, 2020. https://uofuhealth.utah Manuel David Gil-Sierra, PharmD .edu/value/ Marina Sánchez-Hidalgo, PharmD 3. Woods L, Slotkin J, Coleman R. Transforming Health Care. Harvard Business Catalina Alarcón de la

Journal

JAMA OncologyAmerican Medical Association

Published: Feb 23, 2021

References